BRIACELL THERAP (BCTX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of a c ...

Core Insights - BriaCell Therapeutics Corp. announced a significant clinical response in a metastatic breast cancer patient treated with Bria-OTS™, including complete resolution of lung metastasis after four injection cycles [1][5][7] - Bria-OTS™ is a personalized off-the-shelf immunotherapy currently in a Phase 1/2a dose escalation study for metastatic recurrent breast cancer, representing an advancement over BriaCell's previous candidate, Bria-IMT™ [2][6] - The initial patient in the study, a 78-year-old woman, had extensive metastases and showed stable disease elsewhere after treatment, indicating the potential effectiveness of Bria-OTS™ [5][6] Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [8] - The company is exploring the therapeutic potential of Bria-OTS™ not only in metastatic breast cancer but also plans to extend its application to prostate cancer, melanoma, and lung cancer [6][8] Clinical Study Details - The Phase 1/2a clinical trial is designed to evaluate the safety and efficacy of Bria-OTS™ as a monotherapy initially, followed by combination therapy with an immune checkpoint inhibitor [6][7] - Key inclusion criteria for the study include recurrent metastatic breast cancer and at least two prior failed systemic therapy attempts [6]

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 27, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announces that on January 24, 2025 (the "Effective Date"), the Company completed a share consolidation (the "Consolidation") of the Company's issued and outstanding common shares (the "Common Shares") on the basis of one (1) post-Consolidati ...

Financial Performance - BriaCell reported a net loss of $5,802,175 for the three months ended October 31, 2024, compared to a net income of $6,001,543 in the same period of 2023, reflecting a significant change in financial performance [102]. - For the three-month period ending October 31, 2024, the Company reported a loss of $5,829,276 compared to a gain of $5,958,872 for the same period in 2023, primarily due to a significant change in the fair value of the warrant liability [112]. - Net financial income for the three-month period ending October 31, 2024, was $11,714, a significant decrease from $179,822 in the same period of 2023, driven by lower interest income [111]. - The Company has an accumulated deficit of $91,245,872 as of October 31, 2024, up from $85,443,697 as of July 31, 2024 [115]. Operating Expenses - Total operating expenses decreased to $5,152,832 in Q1 2024 from $8,503,028 in Q1 2023, primarily due to reduced research and development costs [102]. - General and administrative expenses decreased to $1,487,491 in Q1 2024 from $1,645,771 in Q1 2023, reflecting cost management efforts [110]. - Research and development expenses for the three months ended October 31, 2024, were $3,665,341, down from $6,857,257 in the same period of 2023, indicating a 46% reduction [102]. Cash Flow and Financing - The Company’s net cash used in operating activities during the period ended October 31, 2024, was $6,955,076, a decrease from $7,605,245 for the same period in 2023 [117]. - Cash gained in financing activities for the period ended October 31, 2024, was $11,960,252, compared to nil for the same period in 2023 [118]. - The Company intends to raise additional capital through debt or equity financings to achieve its business plan objectives, although there is no assurance of success [117]. - The Company’s overall position of cash and cash equivalents increased by $4,930,176 from the period ended July 31, 2024 [117]. Assets and Working Capital - As of October 31, 2024, the Company had total assets of $10,414,330, an increase from $5,872,261 as of July 31, 2024, and a positive working capital of $3,230,459 compared to a negative balance of $3,807,303 [115]. Clinical Studies and Developments - The Bria-IMT™ pivotal Phase 3 study costs amounted to $2,185,543, remaining consistent with the prior year's $2,278,258, highlighting strategic spending optimization [107]. - The one-year survival rate for patients treated with the Bria-IMT™ regimen in the Phase 2 clinical study was reported at 55%, exceeding the current standard of care [98]. - BriaCell is advancing its Bria-IMT™ targeted immunotherapy in a pivotal Phase 3 study for metastatic breast cancer, with 35 clinical sites actively enrolling patients [97]. - The Company has received FDA Fast Track designation for the Bria-IMT™ combination regimen, which could lead to full approval upon positive study results [95]. - The Phase 1/2 study for Bria-OTS™ commenced with the first patient dosed, evaluating its safety and efficacy in combination with an immune checkpoint inhibitor [99]. Foreign Exchange and Investment Strategy - The Company is exposed to foreign exchange risk due to transactions occurring in Canadian Dollars, but a 5% fluctuation would not have a material effect on total loss [132]. - The Company’s investment strategy focuses on capital preservation and supporting liquidity requirements, primarily through cash and cash equivalents [116].

Core Insights - BriaCell Therapeutics Corp. reports significant infiltration of CD8+ "killer" T cells into metastatic breast cancer tumors and lymphatic tissues, indicating a positive response to the Bria-IMT™ plus immune checkpoint inhibitor (CPI) treatment [1][6][7] - The use of CD8 ImmunoPET imaging technology has been validated as a precision diagnostic tool to monitor immune responses in patients, correlating with clinical benefits and tumor marker reductions [2][7] Group 1: Treatment Efficacy - The Bria-IMT™ plus CPI regimen led to the transformation of "cold" tumors into "hot" tumors, suggesting enhanced immune activity against cancer cells [6][7] - In a study involving six patients, 50% showed a decrease in the neutrophil/lymphocyte ratio, indicating immune system activation after treatment [6] Group 2: Imaging Technology - CD8 ImmunoPET imaging was utilized to document the mechanism of action of the Bria-IMT™ regimen, providing insights into its effectiveness in cancer treatment [3][4] - The imaging technology is crucial for identifying pseudo progression in patients who exhibit clinical benefits, distinguishing them from those with actual tumor progression [2][7] Group 3: Clinical Presentation - The findings were presented at the 2024 San Antonio Breast Cancer Symposium, highlighting the potential of the Bria-IMT™ regimen in improving patient outcomes [5][7] - The poster presentation included details such as the abstract number SESS-1069 and emphasized the importance of CD8+ T cells in cancer detection and destruction [5]

Core Viewpoint - BriaCell Therapeutics Corp. has announced a public offering of 7,400,000 common shares and warrants, aiming to raise approximately $5.55 million to support its business objectives and working capital needs [1][2]. Group 1: Offering Details - The public offering price is set at $0.75 per share, with warrants having an exercise price of $0.9375, immediately exercisable for five years [1]. - The offering is expected to close on December 13, 2024, pending customary closing conditions [1]. - ThinkEquity is acting as the sole book-running manager for the offering [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital requirements, general corporate purposes, and advancing business objectives [2]. Group 3: Regulatory Information - The offering is conducted under a shelf registration statement on Form S-3, filed with the U.S. SEC, and a final prospectus supplement will be made available [4].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from [●] to [●] Commission File Number: 001-40101 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or othe ...

I am working in the financial sector. My areas of interest are technology, biotech, pharmaceutical companies, banks and a bit of shipping when an actionable trade passes on my radar.Analyst’s Disclosure: I/we have a beneficial long position in the shares of IPA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company who ...

BRIACELL THERAP (BCTX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a cha ...

On Wednesday, BriaCell Therapeutics BCTX stock traded higher with a session volume of 113.08 million, compared to the average volume of 366.19 thousand, according to data from Benzinga Pro.BriaCell Therapeutics announced overall survival data from its Phase 2 clinical study of Bria-IMT in combination with an immune checkpoint inhibitor (CPI) in late-stage metastatic breast cancer.The company reported a median overall survival of 15.6 months from its most recent patients (treated since 2022) vs. 6.7-9.3 mont ...